Bexson Biomedical announced that it the U.S. Patent and Trademark Office (USPTO) granted a patent for its BB106 ketamine therapy.
Santa Barbara, Calif.-based Bexson’s patent describes pharmaceutical formulations and treatment methods for the ketamine therapy, which the company believes allows for safety, comfort and pharmacokinetics that improve the administration of ketamine through multiple avenues, including the subcutaneous route, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.